The safety, efficacy and regulatory triangle in drug development: Impact for animal models and the use of animals
Owner/Developer: European Journal of Pharmacology
| Country: | Netherlands |
|---|---|
| Languages: | English |
| Url: | http://www.sciencedirect.com/science/article/pii/S0014299915002551 |
| Description: |
In this manuscript we review the connections in the triangle between nonclinical efficacy/safety studies and regulatory aspects, with focus on in vivo testing of drugs. These connections differ for different drugs (chemistry-based low molecular weight compounds, recombinant proteins, cell therapy or gene therapy products). Regarding animal models and their translational value we focus on regulatory aspects and indications where scientific outcomes warrant changes, reduction or replacement, like for, e.g., biosimilar evaluation and safety testing of monoclonal antibodies. On the other hand, we present applications where translational value has been clearly demonstrated, e.g., immunosuppressives in transplantation. Especially for drugs of more recent date like recombinant proteins, cell therapy products and gene therapy products, a regulatory approach that allows the possibility to conduct combined efficacy/safety testing in validated animal models should strengthen scientific outcomes and improve translational value, while reducing the numbers of animals necessary. |
| Category: | Publication |
| Channel: | Website |
| Audience: | Researchers - Scientists - Industry |
| User access: | Restricted access - Fee-based access |
| Updating frequency: | 2015 |
| Relevance: | Replacement - Reduction - Refinement |
| Purpose: | Documentation and information - Regulatory testing - Toxicological and safety evaluation - Efficacy testing |
| Technology/Tools: | Animal testing (in vivo) |
Fant du det du lette etter?
Ja, jeg fant det! Nei, jeg fant det ikke!Takk for din tilbakemelding! Vær oppmerksom på at vi ikke kan kontakte deg hvis ikke du oppgir din epostadresse.
Hva lette du etter?
Gi oss gjerne en tilbakemelding slik at vi kan forbedre informasjonen på siden. På forhånd takk for hjelpen! Vennligst skriv inn din epostadresse hvis du vil ha et svar.
Kontakt oss gjerne på e-post hvis du har spørsmål.